Study Title: A Randomized Controlled Trial of Topical Analgesia Posthemorrhoidectomy (TAPH Trial).

Study Summary:
Postoperative pain remains the greatest problem after hemorrhoidectomy. Pain is hypothesized to arise from bacterial infection, sphincter spasm, and local inflammation. This trial was conducted to assess the effects of metronidazole, diltiazem, and lidocaine on posthemorrhoidectomy pain. A double-blinded randomized controlled factorial trial. This multicenter trial was conducted in Auckland, New Zealand. A total of 192 participants were randomly assigned (1:1:1:1) into 4 parallel arms. Participants were randomly assigned into 1 of 4 groups receiving topical treatment with 10% metronidazole, 10% metronidazole + 2% diltiazem, 10% metronidazole + 4% lidocaine, or 10% metronidazole + 2% diltiazem + 4% lidocaine. Participants were instructed to apply treatment to the anal verge 3 times daily for 7 days. The primary outcome was pain on the visual analog scale on day 4. The secondary outcomes included analgesia usage, pain during bowel movement, and functional recovery index. There was no significant difference in the pain and recovery scores when diltiazem or lidocaine was added to metronidazole (score difference between presence and absence of diltiazem in the formulation: -3.69; 95% CI, -13.3 to 5.94; p = 0.46; between presence and absence of lidocaine: -5.67; 95% CI, -15.5 to 3.80; p = 0.24). The combination of metronidazole + diltiazem + lidocaine did not further reduce pain. Secondary analysis revealed a significant difference between the best (metronidazole + lidocaine) and worst (metronidazole + diltiazem + lidocaine) groups in both pain and functional recovery scores. There were no significant differences in analgesic usage, complications, or return to work between the groups. No clinically important adverse events were reported. The adverse event rate did not change in the intervention groups. Topical metronidazole was used in the control group rather than a pure placebo. There was no significant difference in pain when topical diltiazem, lidocaine, or both were added to topical metronidazole. See Video Abstract . NCT04276298. ANTECEDENTES:El dolor postoperatorio sigue siendo el mayor problema tras hemorroidectom&#xed;a. La hip&#xf3;tesis es que el dolor se debe a infecci&#xf3;n bacteriana, el espasmo esf&#xed;nteriano e inflamaci&#xf3;n local.OBJETIVO:Se realiz&#xf3; un ensayo factorial aleatorizado y controlado para evaluar los efectos del metronidazol, el diltiazem y la lidoca&#xed;na en el dolor posthemorroidectom&#xed;a.DISE&#xd1;O:Ensayo factorial controlado aleatorizado doble ciego.ESCENARIO:Se realiz&#xf3; un ensayo multic&#xe9;ntrico en Auckland, Nueva Zelanda.PACIENTES:Se aleatoriz&#xf3; a 192 participantes (1:1:1:1) en cuatro brazos paralelos.INTERVENCIONES:Los participantes se asignaron aleatoriamente a uno de los cuatro grupos que recibieron tratamiento t&#xf3;pico con metronidazol al 10% (M), metronidazol al 10% + diltiazem al 2% (MD), metronidazol al 10% + lidoca&#xed;na al 4% (ML), o metronidazol al 10% + diltiazem al 2% + lidoca&#xed;na al 4% (MDL). Se indic&#xf3; a los participantes que lo aplicaran en el margen anal 3 veces al d&#xed;a durante 7 d&#xed;as.PRINCIPALES MEDIDAS DE RESULTADO:El resultado primario fue el dolor en la escala anal&#xf3;gica visual en el d&#xed;a 4. Los resultados secundarios incluyeron el uso de analgesia, el dolor al defecar y el &#xed;ndice de recuperaci&#xf3;n funcional.RESULTADOS:No hubo diferencias significativas en las puntuaciones de dolor y recuperaci&#xf3;n cuando se a&#xf1;adi&#xf3; diltiazem o lidoca&#xed;na al metronidazol (diferencia de puntuaci&#xf3;n entre la presencia y la ausencia de D en la formulaci&#xf3;n: -3.69; IC del 95%: -13.3; 5.94; p = 0.46; entre la presencia y la ausencia de L: -5.67; IC del 95%: -15.5; 3.80; p = 0.24). La combinaci&#xf3;n de MDL no redujo m&#xe1;s el dolor. El an&#xe1;lisis secundario revel&#xf3; una diferencia significativa entre los grupos mejor (ML) y peor (MDL) tanto en las puntuaciones de dolor como en las de recuperaci&#xf3;n funcional. No hubo diferencias significativas en el uso de analg&#xe9;sicos, las complicaciones o la reincorporaci&#xf3;n al trabajo entre los grupos. No se notificaron eventos adversos cl&#xed;nicamente importantes. La tasa de eventosadversos no cambi&#xf3; en los grupos de intervenci&#xf3;n.LIMITACIONES:Se utiliz&#xf3; metronidazol t&#xf3;pico en el grupo de control, en lugar de un placebo puro.CONCLUSIONES:No hubo diferencias significativas en el dolor cuando se a&#xf1;adi&#xf3; diltiazem t&#xf3;pico o lidoca&#xed;na, o ambos, al metronidazol t&#xf3;pico. ( Traducci&#xf3;n-Dr. Jorge Silva Velazco )Identificador de registro del ensayo cl&#xed;nico:NCT04276298.

Methodology:

1. Study Type
- Clinical trial
- Publication Date: 2024
- DOI: 10.1097/DCR.0000000000003419

2. Keywords


3. Key Findings
- Secondary analysis revealed a significant difference between the best (metronidazole + lidocaine) and worst (metronidazole + diltiazem + lidocaine) groups in both pain and functional recovery scores

This study provides insights into:
- General research methodology and outcomes
